December 10th 2020, 11:45am
Lee Schwartzberg, MD, FACP, chief medical director of West Cancer Center and chief medical officer of OneOncology, discusses the approvals of pembrolizumab and sacituzumab govitecan for patients with triple-negative breast cancer.
December 10th 2020, 2:45am
During the San Antonio Breast Cancer Symposium 2020, Lajos Pusztai, MD, DPhil, of Yale Cancer Center, reviewed recently established and emerging biomarkers in both the neoadjuvant and metastatic breast cancer settings.
December 9th 2020, 9:00pm
Yuan Yuan, MD, PhD, medical oncologist at City of Hope, discusses an ongoing study on ipatasertib with chemotherapy and atezolizumab presented at the San Antonio Breast Cancer Symposium 2020.
December 9th 2020, 2:00pm
City of Hope's Joanne Mortimer, MD, a medical oncologist and director of the Women's Cancer Program, discusses a poster presentation from the 2020 San Antonio Breast Cancer Symposium.
December 9th 2020, 1:30pm
A panel at the 2020 San Antonio Breast Cancer Symposium discussed 3 new drug approvals from the past year, highlighting changes in the treatment landscape across multiple breast cancer types.
December 8th 2020, 11:00pm
Rachel Jimenez, MD, radiation oncologist at Massachusetts General Hospital, outlines the prevalence of cardiac toxicity, as well as the short-term and long-term impacts.
December 8th 2020, 9:15pm
The first session at the San Antonio Breast Cancer Symposium 2020 looked at how the COVID-19 pandemic is disproportionately affecting care for minority patients.
December 8th 2020, 3:23pm
As more data have become available, we are seeing more and more patients receiving chimeric antigen receptor (CAR) T-cell therapy in the community setting, noted Karl Kilgore, PhD, senior research scientist at Avalere Health.
December 8th 2020, 3:00pm
A late-breaking study presented at the American Society of Hematology annual meeting raises the specter of whether interventions can occur decades before a blood cancer would appear.
December 8th 2020, 4:45am
The treatment appeared to live up to its billing of having fewer off-target effects in studies presented at the American Society of Hematology.